We are live on
!
Find out more
HP
HealthInvest Partners Portfolio holdings
AUM
$372M
1-Year Est. Return
59.89%
This Fund
S&P 500
This Quarter
Est. Return
+13.65%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$128M
AUM Growth
–
Cap. Flow
+$119M
Cap. Flow
% of AUM
93.48%
Top 10 Holdings %
Top 10 Hldgs %
52.35%
Holding
45
New
45
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$9.82M |
| 2 |
Eli Lilly
LLY
|
+$9.23M |
| 3 |
Gilead Sciences
GILD
|
+$7.7M |
| 4 |
Cencora
COR
|
+$7.6M |
| 5 |
Merck
MRK
|
+$6.82M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
UnitedHealth
UNH
$368B
| $9.69M | 7.59% |
+18,408
| New | +$9.82M |
|
|
2
Eli Lilly
LLY
$1.05T
| $9.21M | 7.21% |
+15,805
| New | +$9.23M |
|
|
3
Gilead Sciences
GILD
$162B
| $8.02M | 6.28% |
+98,974
| New | +$7.7M |
|
|
4
Cencora
COR
$61.3B
| $7.99M | 6.26% |
+38,925
| New | +$7.6M |
|
|
5
Merck
MRK
$317B
| $7.16M | 5.6% |
+65,675
| New | +$6.82M |
|
6
Thermo Fisher Scientific
TMO
$212B
| $6.06M | 4.74% |
+11,415
| New | +$5.53M |
|
7
Cardinal Health
CAH
$55.2B
| $4.84M | 3.79% |
+48,000
| New | +$4.76M |
|
8
Harmony Biosciences
HRMY
$2.23B
| $4.68M | 3.67% |
+145,000
| New | +$4.05M |
|
9
Amgen
AMGN
$218B
| $4.61M | 3.61% |
+16,023
| New | +$4.37M |
|
10
Centene
CNC
$31.8B
| $4.6M | 3.6% |
+62,000
| New | +$4.47M |
|
11
Molina Healthcare
MOH
$10.1B
| $4.52M | 3.54% |
+12,500
| New | +$4.41M |
|
12
Bristol-Myers Squibb
BMY
$130B
| $4.52M | 3.53% |
+88,000
| New | +$4.62M |
|
13
Cigna
CI
$71.6B
| $4.49M | 3.52% |
+15,000
| New | +$4.38M |
|
14
Elevance Health
ELV
$84.3B
| $4.48M | 3.51% |
+9,500
| New | +$4.39M |
|
15
Stryker
SYK
$129B
| $3.83M | 3% |
+12,802
| New | +$3.59M |
|
16
Boston Scientific
BSX
$71.9B
| $3.75M | 2.93% |
+64,806
| New | +$3.46M |
|
17
Vertex Pharmaceuticals
VRTX
$122B
| $3.71M | 2.91% |
+9,130
| New | +$3.37M |
|
18
Regeneron Pharmaceuticals
REGN
$78.7B
| $3.49M | 2.74% |
+3,979
| New | +$3.28M |
|
19
AbbVie
ABBV
$429B
| $3.28M | 2.57% |
+21,196
| New | +$3.09M |
|
20
IQVIA
IQV
$37.9B
| $2.39M | 1.87% |
+10,340
| New | +$2.12M |
|
21
DexCom
DXCM
$31.2B
| $2.24M | 1.75% |
+18,057
| New | +$1.84M |
|
22
Neurocrine Biosciences
NBIX
$16.1B
| $1.66M | 1.3% |
+12,617
| New | +$1.45M |
|
23
Edwards Lifesciences
EW
$51B
| $1.59M | 1.24% |
+20,815
| New | +$1.45M |
|
24
Option Care Health
OPCH
$3.51B
| $1.25M | 0.98% |
+37,223
| New | +$1.14M |
|
25
Pfizer
PFE
$148B
| $1.23M | 0.97% |
+42,820
| New | +$1.29M |
|
Similar funds
KP
TCM
SAAM
PAA
PC
BOCH
GIP
PC
HealthInvest Partners's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for HealthInvest Partners, which disclosed 45 positions worth $128M. Its ten largest holdings account for 52% of the portfolio.
Its largest position is UnitedHealth: 18,408 shares worth $9.69M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- HealthInvest Partners's largest Q4 2023 buy was UnitedHealth: 18,408 shares worth $9.69M.
- HealthInvest Partners's ten largest holdings make up 52% of its $128M portfolio in Q4 2023.
- HealthInvest Partners disclosed 45 positions in Q4 2023, its first 13F filing on record.
Based on HealthInvest Partners's 13F filing for Q4 2023, filed 30 Jan 2024.